This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. We are committed to delivering groundbreaking therapies that address key unmet medical needs.
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. We are currently advancing three biologic product candidates in clinical studies for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion.
Leveraging our team’s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies that satisfy key unmet medical needs and improve patient outcomes.
Active human trials
In development
Diverse expertise
To become a global leader in musculoskeletal therapeutics by transforming scientific innovation into life-changing treatments for patients worldwide.
To discover, develop, and deliver groundbreaking therapies for serious musculoskeletal diseases, driven by science, integrity, and patient-centric values.
Respect, equality, scientific excellence, collaboration, and commitment to employee growth and career development.
Advancing innovative biologic therapies for serious musculoskeletal conditions with high unmet medical need.
Bispecific Antibody
Monoclonal Antibody
Recombinant Fusion Protein
Gene Therapy Candidate
Small Molecule Inhibitor
Peptide Therapeutic
Cell-Based Therapy
Therapeutic Fusion Protein
Addressing critical unmet needs in musculoskeletal health
Become an Angitian! We are a global company with a diverse team united by a culture of respect, equality, and scientific excellence.
We are committed to fostering employee growth, career development, and innovation. If you're passionate about transforming lives through science, we want to hear from you.
AGA2115 also received Orphan Drug Designation from EMA.
Read MoreFor more information about our pipeline, partnerships, or media inquiries, please visit our official website.
Visit Official WebsiteNotice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact [email protected]
如果您是其他域名合作 也请联系[email protected]